Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D-CAR-NK92 in Relapsed/Refractory Solid Tumors
NCT05528341Phase 1Recruiting
- Sponsor
- Xinxiang Medical University
- Start
- Jan 2023
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NKG2D-CAR-NK92 in solid tumor, breast cancer, lung cancer and 7 more, sponsored by Xinxiang Medical University. Primary endpoint: Number of participants with adverse events at 3 months. Started Jan 2023; status: recruiting.
02
Drugs
NKG2D-CAR-NK92
03
Conditions
solid tumorbreast cancerlung cancergastric cancer (GC)ovarian cancer
Beyond the preview
Go deeper on NCT05528341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528341.